Company Disclosure

Financial Highlights – Q1 FY2026-27 (Consolidated)

The company reported consolidated financial results for the quarter ending June 2026:

  • Revenue from Operations: ₹3,349.08 lakh (₹33.49 crore), compared to ₹2,223.46 lakh in Q1 FY2025-26
  • Profit Before Tax: ₹1,321.95 lakh, compared to ₹1,586.35 lakh in Q1 FY2025-26
  • Profit After Tax: ₹897.84 lakh (₹8.98 crore), compared to ₹1,264.45 lakh in Q1 FY2025-26
  • Paid-Up Equity Share Capital: ₹856.84 lakh (unchanged)
  • Reserves: ₹26,243.65 lakh (unchanged)
  • EPS: ₹10.48, compared to ₹14.76 in Q1 FY2025-26

Note: These consolidated numbers include CORIS sales of ₹862.83 lakh and CORIS negative EBITDA of ₹(352.24) lakh. Q1 FY2025-26 figures did not include Coris numbers as the consolidation date was August 29, 2025.

Business Division Performance

Molecular Diagnostics (MDx) Division

Overview: Founded November 2010 (15 years in molecular diagnostics)

Core Focus: Design, development and manufacture of:

  • qPCR Assays (TRUPCR®)
  • Lateral Flow Assays (TRURAPID®)
  • NGS Assays (TRUNGS®)
  • Digital PCR Assays (TRUdPCR®)

Business Metrics:

  • Product Portfolio: 120+ Molecular Diagnostic Assays Developed
  • Customer Reach: 1,000+ labs/hospitals in India across 100+ cities; 70+ countries internationally
  • Certifications: ISO 13485:2016 (BSI, UK), Licensed by CDSCO, IVDR compliant (EU 2017/746)

Q1 FY2026-27 Performance:

  • Revenue from Operations: ₹3,205.73 lakh (including TRUPCR Europe: ₹542.91 lakh and Coris: ₹862.83 lakh)
  • Exports: ₹596.28 lakh compared to ₹430.90 lakh in Q1 FY2025-26 (38% growth)
  • 3B Standalone business grew by 19% in Q1 FY2026-27

Agrochemicals Division

Focus Areas: Government procurement (via GeM platform), exports to Bangladesh

Debt Status: Minimal debt

Export Performance:

  • Q1 FY2026-27: ₹58.99 lakh
  • Q1 FY2025-26: ₹53.58 lakh

Product Portfolio:

  • Chemicals: 112 products (Insecticides, Antibacterials, Fungicides, Herbicides, Public Health, Microfertilizers, Chelated Zinc, Plant Growth Regulators)
  • Biologicals: 25 products (Bio pesticide, Bio fungicide, Bio fertilizers, Bio nematicides, Public Health, Health & Hygiene, Repellents)

Strategic Developments & Future Outlook

Coris BioConcept Acquisition Performance

Acquired on August 29, 2025. Q1 FY2026-27 highlights:

  • Revenue: EUR 796K with EBITDA loss of EUR 325K
  • Q1 FY2025-26: Revenue EUR 788K with EBITDA loss of EUR 414K (21% reduction in loss)
  • Historical trend: Q1-Q2 loss making; Q3-Q4 profitable due to HAT order deliveries
  • Received HAT order confirmation for EUR 1.41M for December 2026 delivery (compared to EUR 1.35M in December 2025)
  • HAT Contract: Belgium Govt. order of EUR 6.0M received February 2024 (4-year supply)
  • AMR products grew 12% (70% of sales); other categories declined 54% due to Chinese competition

Growth Targets & Strategy

Market Position: 15% market share in estimated ₹500-600 crore Indian MDx market

FY2026-27 Outlook:

  • Industry projected growth: 8-10% CAGR
  • Company target: 15-20% growth (domestic and export)
  • Growth drivers: Extensive product portfolio, market presence, high-quality products

Strategic Priorities:

1. Market Penetration: Expand product range with current customers/channel partners

2. Portfolio Expansion: New assays in qPCR, Lateral flow immunoassay, NGS

3. Geographical Reach: Enter untapped regions through local distributors

4. Mergers & Acquisitions: Pursue strategic M&A opportunities

Regulatory Progress

IVDR Certification:

  • Regulation (EU) 2017/746 applicable from May 26, 2026
  • Transition period until December 31, 2028 for legacy devices
  • BSI Group appointed as Notified Body
  • Successfully passed IVDR-aligned QMS audits in November 2025
  • Technical evaluation of product groups underway

US FDA Registration: Coris started working on US FDA registration for RESIST-5 AMR (1-2 year timeline)

Product Development & Launches

Newly Launched Products:

  • TRURAPID® RESIST-5 OKNVI Rapid Test (Carbapenem resistance)
  • TRURAPID® RESIST ACINETO Rapid Test (Acinetobacter carbapenem resistance)
  • TRURAPID® RESIST CTX-M Rapid Test (Cephalosporin resistance)
  • TRUPCR® Skin and Nail Fungus Panel Kit
  • TRUPCR® Aspergillus Detection & Differentiation Kit

Upcoming Launches:

  • BRCA Plus Kit (germline/somatic mutations for breast, ovarian, prostate cancers)
  • MTB - MDR NGS Kit (Advanced Genomic Profiling of TB Drug Resistance)

Digital PCR: Commercial launched in Q3 FY2025-26 (nominal sales currently)

Sales & Distribution Model

India Sales Models:

  • Tender Sales: 5-7% of total sales
  • Contractual/Reagent Rental Model: 20-25% projected contribution
  • Other Supplies: 65-70% of total sales

Credit Policy: Liberal credit policy implemented to sustain competition, resulting in higher debtor levels

Global Presence: 70+ countries across Europe, Middle East, APAC, LATAM, North America

Capacity Utilization

Currently operating at ~65% of installed capacity, with potential to reach full capacity during seasonal demand spikes (vector-borne disease outbreaks, flu season). Lean season utilization around ~50%.

Corporate Social Responsibility (CSR)

The company supports multiple initiatives through its CSR policy focused on Health, Education & Employment, and Community Responsibility. Key partnerships include:

  • Army Wives Welfare Association (AWWA)
  • ARUSHI (upgrading Occupational Therapy Centre)
  • Sightsavers ("Netra Vasant" Rural Eye Health Programme)
  • Friends of Tribals Society (Ekal Vidyalaya)
  • Prerna Sewa Trust, Bhopal
  • Sahara Saksharta
  • Cachar Cancer Hospital & Research Centre

Recognitions & Awards

  • National MSME Award 2018 (Presented by Hon. President of India)
  • Outstanding Achievement Award (2017 & 2022) by MP Chambers of Commerce & Industries
  • Featured in FORBES INDIA DGEMS 2023 Top 200 Global Potential Companies
  • Selected as part of "Select 200 Companies" with global business potential at DGEMS2023

#Tags: #3BBlackBio #Q1Results #MolecularDiagnostics #SEBIDisclosure #RegulatoryCompliance #FinancialUpdate #Neutral